Ruth Kang'ong'oi, AfricaNews reporter in Kigali, Rwanda
After approval from the Medical Ethics Committee this week, Rwandan Project Ubuzima will spend the next three years conducting a research on an Anti-HIV gel for women which is part of the microbicide medical products and is believed to reduce the risk of HIV infection among women.

The use of microbicides to fight HIV infection was first embraced last year by the Joint United Nations Programme on HIV/AIDS during an international AIDS conference in Vienna.
Dr. Justin Wane, the Chairperson of the committee said that Based on the evaluation of the content and methodology of the research, the Ministry of Health and the Ethics Committee approved the proposal.
The research is based on microbicide products that contain an Anti retroviral compound, Dapirivine that is being developed as vaginal gels, films and rings to help protect women from HIV infection during sexual intercourse.
The Scientific Manager at the project, Evelyne Kestelyn, said that 400 to 800 participants are expected to enroll in the trials where each of them will engage in the screening process for up to four weeks prior to enrolment.
“In these trials, the participants will use the gel for a period of 15 to 33 months,” said Kestelyn adding that each participant will have an additional six weeks of follow-up to identify HIV-1 seroconversions that are not detected during the product-use period. (Seroconversion is the change from HIV-negative to HIV-positive status during blood testing.)
Kestelyn said that the study will take approximately three years In Rwanda meaning that they will probably start enrolling mid this year, She further added that during the clinical trials, the health and safety of the volunteers will be put as first priority under standard clinical procedures, which are approved and monitored by regulatory authorities.
In a potential breakthrough in the prevention of AIDS, researchers reported that a vaginal gel containing an existing AIDS drug can cut in half a woman's chances of getting HIV from an infected partner.